Johnson & Johnson to buy Synthes for $21.3 billion

By Bizclik Editor

 

Johnson & Johnson Inc. announced Wednesday that it plans to buy Swiss medical-device maker Synthes Inc. for $21.3 billion in order to expand its expanding orthopedic-device sector. Reports from the past weeks suggested the company would buy Synthes for about $20 billion. The final price of the deal won’t be determined until 10 days before closing, which will include cash and stock options. Analysts believe the deal may not happen for at least a year.

Under the terms of the deal, Synthes shareholders would receive 55.65 Swiss francs in cash and 103.35 in Johnson & Johnson common stock for each share. Johnson & Johnson already operate several orthopedic-device businesses under the brand DePuy. Once the deal closes, DePuy and Synthes will make for the largest segment of the company’s medical device division. 

“Orthopedics is a large and growing $37 billion global market and represents an important growth driver for Johnson & Johnson. Synthes is widely respected for its innovative high-quality products, world-class R&D capabilities, its commitment to education, the highest standards of service, and extensive global footprint,” said William Weldon, Johnson & Johnson chief executive.

See top stories in the WDM Content Network:
Top Ten Biggest Brands 
• Click here to read the latest edition of Business Review USA 

Merck & Co., the second-largest U.S. drug maker has also increased a share repurchase program by $5 billion, which raises the total amount of stock that can be bought back to $6.4 billion. According to a statement, Merck drew $10.8 billion in cash from operating activities last year and agreed to split sales for its arthritis drug Remicade with Johnson & Johnson, ending a dispute that assisted in driving Merck’s stock down over the last year. 





 

Share

Featured Articles

Sustainability, ESG, net zero in focus at must-attend event

Sustainability takes centre stage at two-day hybrid conference featuring thought leaders covering circular economy, scope 3, ESG, B Corp, net zero, DE&I

Must-attend sustainability events for executives in 2022/23

Discuss and debate the most pressing issues around sustainability at these nine executive events – from London to Abu Dhabi, San Diego to Singapore

Meet the CEO on a mission to nurture women leaders in Africa

The argument for women leaders in Africa is compelling, yet numbers are small. But one female leader is on a mission to change that – Awamary Lowe-Khan

BCG's Daniel Weise on supply chain and procurement strategy

Leadership & Strategy

Flexible work perks heat up as the war on talent rages

Human Capital

Meet the COO: Former Israel Defense Force cyber lead Parnes

Technology & AI